The clinical, pathological features and expression of Ki-67 and COX-2 in severe reflux esophagitis and Barrett's esophagus

Journal of Sichuan University (Medical Science)

Volumn 36, Issue 2, 2005, Pages 207-209

  Chen, Xi ^a   Ouyang, Qin ^a   Zhang, Wen Yan ^a   Li, Xi Shi ^a   Liang, Hong Liang ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Barrett's esophagus; COX 2; Ki 67; Severe reflux esophagitis

Indexed keywords

CYCLOOXYGENASE 2; KI 67 ANTIGEN; PEROXIDASE;

ADULT; AGED; ARTICLE; BARRETT ESOPHAGUS; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; ENDOSCOPY; ESOPHAGUS MUCOSA; FEMALE; HUMAN; MALE; PATHOLOGY; PROTEIN EXPRESSION; REFLUX ESOPHAGITIS; RETROSPECTIVE STUDY;

EID: 16244362391     PISSN: 1672173X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Dolan K, Sutton R, Walker SJ, et al. New classification of oesophagel and gastric carcinomas derived from changing patterns in epidemiology. Br J Cancer, 1999;80(5-6):834.
2. Thomas P, Doddoli C, Lienne P, et al. Changing patterns and surgical results in adenocarcinoma of Barrett's esophagus. British Journal of Surgery, 1997;84(1):119.
3. Clive D, Morris MB, Ch B, et al. Cyclooxygenase-2 expression in the Barrett's metaplasia-dysplasia-adenocarcinoma sequence. The American Journal of Gastroenterology, 2002;96(4):990.
4. Shirvani V, Ouatu-lascar R, Kaur B, et al. Cyclooxygenase-2 expression in the Barrett's esophagus and adenocarcinoma: ex vivo induction by bile and acid exposure. Gastroenterology, 2000;118(3):487.
5. Farrow DC, Vaughan TL, Hansten PD, et al. Use of aspirin and other nonsteriodal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev, 1998;7(2):97.
6. Navtej S, Buttar, Kenneth K, et al. Chemoprevention of esophageal adenocarcinoma by COX-2 inhibitors in an animal model of Barrett's esophagus. Gastroenterology, 2002;122(4): 1101.